Royal Bank of Canada Increases ResMed (NYSE:RMD) Price Target to $200.00

ResMed (NYSE:RMD – Free Report) had its price target raised by Royal Bank of Canada from $187.00 to $200.00 in a report issued on Friday, Benzinga reports. The firm currently has a sector perform rating on the medical equipment provider’s stock. A number of other research analysts have also recently commented on the stock. Oppenheimer […]

Related Keywords

United Kingdom ,Canada ,Great Lakes ,Canada General ,Peterc Farrell , ,Resmed Company Profile ,Benjaminf Edwards Company Inc ,Mv Capital Management Inc ,Great Lakes Advisors ,Keycorp ,Harfst Associates Inc ,Jpmorgan Chase Co ,Resmed Inc ,Needham Company ,Royal Bank ,Gulf International Bank United Kingdom Ltd ,Free Report ,Moderate Buy ,Med Stock Down ,Get Free Report ,Director Peter ,General Counsel Michael ,International Bank United Kingdom Ltd ,Lakes Advisors ,Med Inc ,Respiratory Care ,Resmed Daily ,Resmed ,Nyse Rmd ,Rmd ,Medical ,76115210 ,Boost Price Target ,Royal Bank Of Canada ,